MarginsXMarginsX
Home › Markets › Health Care › IMMX

Immix Biopharma Inc. (IMMX)

IMMX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.48
-4.59% on the day
Market cap
$626.9M
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerIMMX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001873835
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
85.6 months
$320.3M cash at September 30, 2026
Share count, 1 year
+149.6%
2025-11-05 to 2026-10-30 · +321.9% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$10K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$320.3M cash; operating cash flow -$11.2M a quarter.Report 2026-09-30
Shares outstanding83,812,456 (2026-10-30); 33,577,873 a year earlier; 19,867,224 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the marketLatest 2026-09-29
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCrowe LLP, Los Angeles, California, United StatesPCAOB Form AP 2026-03-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $10K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$13.9M-$12.3M$320.3MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
Not filed-$11.6M-$11.7M$225.5MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2026
2026-03-31
Not filed-$10.1M-$9.8M$79.3MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2025
2025-12-31
Not filed-$10.6M-$11.0M$93.9MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q3 2025
2025-09-30
Not filed-$7.6M-$5.9M$15.9MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2025
2025-06-30
Not filed-$6.6M-$5.3M$11.6MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2025
2025-03-31
Not filed-$4.5M-$1.7M$15.9MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2024
2024-12-31
Not filed-$4.8M-$1.5M$17.7MNo debt tagsNeeds four quarters10-K/A 2026-03-27

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-09-29
Latest annual report10-K/A2026-03-27
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-04-06

Source: SEC EDGAR submissions feed, 246 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.7%
1 month-9.8%
3 months-28.2%
Year to date+49.9%
1 year+117.2%
From 52-week high-45.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ABUSArbutus Biopharma Corporation$4.04-1.22%$619.3M
DSGNDesign Therapeutics Inc.$9.92-5.25%$635.2M
OLMAOlema Oncology Inc.$7.36-2.65%$644.8M
ANLAdlai Nortye Group Ltd.$10.03-5.47%$645.9M
BCAXBicara Therapeutics Inc.$9.75-2.69%$647.3M
GERNGeron Corporation$0.9419-2.60%$606.8M
KURAKura Oncology Inc.$7.09-8.75%$651.4M
NVCTNuvectis Pharma Inc.$19.11-5.58%$657.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier